EMOTICON: Emotional Freedom Techniques to Reduce Patient Reported Cognitive Complaints in Cancer Survivors
Study Details
Study Description
Brief Summary
The aim of this study is to further validate the CDT as a screening tool for identifying elderly cancer patients in need of a more in-depth cognitive evaluation within comprehensive geriatric assessment (CGA) and to validate the pre-defined cut-off score of ≤ 4 according to the Freund scoring system. All geriatric patients that are diagnosed with cancer will be screened by the oncology clinical nurse specialists attached to the respective multi-disciplinary clinics with the VES-13 and G8 questionnaire. Patients that screen positive, will be offered referral to the multi-disciplinary onco-geriatric program where a member of the research team will implement a full geriatric evaluation under supervision of the medical oncologist and/or geriatrician who will then formulate recommendations and might suggest referral to other health care providers. Individual results and survival data of all the patients that have given their informed consent will be registered in a database.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
In this trial the investigators aim to establish whether Emotional Freedom Techniques (EFT) can reduce cognitive complaints in cancer survivors. All consenting patients aged 18 years or above, who have been diagnosed with a solid tumour of hematologic malignancy and who have completed or are in the late phase of a chemotherapy, radiotherapy, anti-hormonal or targeted therapy treatment, can participate in this trial. Patients should suffer from subjective cognitive complaints based on a score of 43 or more on the Cognitive Failure Questionnaire (CFQ). These patients will be randomly assigned to either the control or intervention group. Patients in the intervention group will be scheduled to receive an 8-week EFT intervention program. Other patients will be placed on an 8-week wait list after which patients will also start the EFT program.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Intervention group Patients assigned to intervention group receive an 8-week EFT-program |
Behavioral: Emotional Freedom Techniques
|
| No Intervention: Control group Patients assigned to control group are placed on a waitlist for a period of 8 weeks |
Outcome Measures
Primary Outcome Measures
- Change in cognitive complaints measured by Cognitive Failure Questionnaire [Week 8, 16, 24]
Score of <43 on the Cognitive Failure Questionnaire ; Minimum value: 0; Maximum value: 100; Higher scores mean worse outcome
Secondary Outcome Measures
- Change in psychological distress measured by Distress Thermometer [Week 8, 16, 24]
Reduction in the score on the Distress Thermometer ; Minimum value: 0; Maximum value: 10; Higher scores mean worse outcome
- Change in fatigue measured by Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale [Week 8, 16, 24]
Reduction in score on FACIT Fatigue scale ; Minimum value: 0; Maximum value: 52; Higher scores mean worse outcome
- Change in quality of life measured by the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 [Week 8, 16, 24]
Improvement of the scores on the Global Health scale, functional scale and symptom scale ; Minimum value: 30; Maximum value: 126; Higher scores mean better outcome
- Chang in quality of life measured by EQ-5D-3L [Week 8, 16, 24]
Improvement on the score on the EQ-5D-3L; Minimum value: -0.285; Maximum value: 1; Higher scores mean better outcome
- Change in long-term quality of life measured by the EuroQol EQ-5D-3L [6 months and 12 months]
Improvement on the score on the EQ-5D-3L; Minimum value: -0.285; Maximum value: 1; Higher scores mean better outcome
- Number of cancer survivors presenting with cognitive complaints as measured by Cognitive Failure Questionnaire [Week 8, 16, 24]
Number of cancer survivors presenting with cognitive complaints as measured by Cognitive Failure Questionnaire
- Influence of age on cognitive complaints in cancer survivors [Week 8, 16, 24]
Interaction effect of age and CFQ score
- Influence of gender on cognitive complaints in cancer survivors [Week 8, 16, 24]
Interaction effect of gender and CFQ score
- Influence of distress on cognitive complaints in cancer survivors as measured by Distress Thermometer [Week 8, 16, 24]
Interaction effect of distress and CFQ score
- Influence of fatigue (FACIT-Fatigue Scale) on cognitive complaints in cancer survivors [Week 8, 16, 24]
Interaction effect of fatigue and CFQ score
- Influence of cancer type on cognitive complaints in cancer survivors [Week 8, 16, 24]
Interaction effect of cancer type and CFQ score
- Influence of cancer stage on cognitive complaints in cancer survivors [Week 8, 16, 24]
Interaction effect of cancer stage and CFQ score
- Influence of the received treatment on cognitive complaints in cancer survivors [Week 8, 16, 24]
Interaction effect of treatment and CFQ score
- Change in depressive symptoms measured by Beck Depression Inventory II [Week 8, 16, 24]
Reduction in score on Beck Depression Inventory II ; Minimum value: 0; Maximum value: 63; Higher scores mean worse outcome
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients should have reached a minimum age of 18 years at the time of enrolment
-
Histologically confirmed diagnosis of a solid cancer or hematologic malignancy
-
Patients should have received chemo- or radiotherapy, targeted therapy of hormonal treatment before enrollment (active treatment with anti-hormonal therapy or brachytherapy is allowed)
-
Patients can be included in the latest phase of their chemotherapy, radiotherapy, anti-hormonal or targeted therapy treatment
-
Patients should have been treated with curative intent or have an expected life expectancy of at least 5 years
-
Patients must suffer from subjective cognitive complaints based on the Cognitive Failure Questionnaire (cut-off ≥ 43)
-
Patients should be able to adequately communicate in Dutch or French
-
Patients should present with a sufficient mental and physical functional status (according to investigator's judgment)
Exclusion Criteria:
-
Patients who received a treatment with palliative intent
-
Patients showing signs of mental deterioration
-
Patients suffering from an organic brain syndrome
-
Patients who are alcohol or drug dependent
-
Patients with a major psychiatric or neurologic disorder that could potentially invalidate assessment; a prior or current diagnosis of a depressive, anxiety or adjustment disorder is allowed
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | General Hospital Klina Brasschaat | Brasschaat | Belgium | 2930 | |
| 2 | Brussels University Hospital | Brussels | Belgium | 1090 | |
| 3 | General Hospital Groeninge | Kortrijk | Belgium | 8500 |
Sponsors and Collaborators
- General Hospital Groeninge
- Universitair Ziekenhuis Brussel
- AZ Klina
Investigators
- Principal Investigator: Philip R Debruyne, MD, PhD, MSc, FRCP, az groeninge
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AZGS2016034